Results 11 to 20 of about 16,400 (171)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs [PDF]

Scientific Reports, 2017
AbstractPatients with low hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA suppression by nucleos(t)ide analogues (NAs) achieve high rate of HBsAg loss through switching to PegIFNα in pre-registration study. The aim of this study was to achieve higher rate of HBsAg loss through extended PegIFN treatment. 98 patients with HBsAg 
Huang, Jing, Zhang, Ka, Chen, Wenli, Liao, Jinyao, Luo, Xiaodan, Chen, Ren   +5 more
openaire   +3 more sources

Long‐term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir‐containing antiretroviral therapy [PDF]

HIV Medicine, 2023
AbstractObjectivesImproving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti‐hepatitis B virus agents being developed. We evaluated long‐term qHBsAg trajectories in persons with HIV and HBV during tenofovir‐containing antiretroviral therapy
Begré, Lorin, Boyd, Anders, Salazar-Vizcaya, Luisa, Suter-Riniker, Franziska, Béguelin, Charles, Rockstroh, Jürgen K, Günthard, Huldrych F, Calmy, Alexandra, Cavassini, Matthias, Stöckle, Marcel, Schmid, Patrick, Bernasconi, Enos, Levrero, Massimo, Zoulim, Fabien, Wandeler, Gilles, Rauch, Andri, Swiss HIV Cohort Study (SHCS)   +16 more
core   +7 more sources

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss [PDF]

The Journal of Infectious Diseases, 2011
Nucleos(t)ide analogues strongly inhibit viral replication in chronic hepatitis B (CHB) infection, but knowledge of their long-term effect on serum hepatitis B surface antigen (HBsAg) levels and HBsAg loss is lacking. Seventy-five CHB patients with virological response (VR) to ETV or TDF were included. HBsAg decline 2 years after VR was most pronounced
Zoutendijk, Roeland, Hansen, Bettina, van Vuuren, Hanneke, Boucher, Charles, Janssen, HLA   +4 more
openaire   +3 more sources

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss. [PDF]

Aliment Pharmacol Ther
BACKGROUND AND AIMS: Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long-term follow-up in a prospective
Hume SJ, Hall S, Burns G, Vogrin S, Tassone D, Desmond P, Ratnam D, Levy MT, Sawhney R, Nicoll A, Valaydon Z, Strasser SI, Ngu M, Sinclair M, Meredith C, Matthews GV, Visvanathan K, Holmes JA, Thompson AJ.   +18 more
europepmc   +2 more sources

Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe. [PDF]

JHEP Rep
BACKGROUND & AIMS: HBsAg loss improves clinical outcomes in persons with HIV and HBV coinfection. We aimed to evaluate if hepatitis B core-related antigen and circulating HBV RNA levels were associated with HBsAg loss in Euro-B, a multi-cohort ...
Begré L, Boyd A, Plissonnier ML, Testoni B, Béguelin C, Suter-Riniker F, Scholtès C, Rockstroh JK, Lacombe K, Peters L, Heil M, Levrero M, Rauch A, Zoulim F, Wandeler G, Swiss HIV Cohort Study, EuroSIDA and French HIV/HBV and Biliver cohorts, Members of the EuroSIDA Study Group, Members of the French HIV/HBV and Biliver cohorts.   +18 more
europepmc   +2 more sources

HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy. [PDF]

, 2023
Background & Aims: Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up.
Dalekos GN, Yuen MF, Sonneveld MJ, Maasoumy B, Brakenhoff SM, Agarwal K, Papatheodoridis G, Tanaka Y, Buti M, Park JY, Ahn SH, Wedemeyer H, Chiu SM, Kaewdech A, Berg T, van Bömmel F, Carey I, Chen CH, Papatheodoridi M, Piratvisuth T, Janssen HL, Zoulim F, Seto WK, Colombatto P, Cornberg M, Brunetto MR, Boonstra A, Erler NS   +27 more
core   +3 more sources

Correction: Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss. [PDF]

Virol J
Gao N, Wu H, Li B, Yu H, Wu L, Zhang J, Zhang N, Lin B, Zhao Q, Gao Z.   +9 more
europepmc   +3 more sources

Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue. [PDF]

Liver Res, 2023
Background and aims: The primary goal of chronic hepatitis B (CHB) treatment is to reduce hepatitis B surface antigen (HBsAg). T helper 17 (Th17) and regulatory T (Treg) cells are essential for the development of CHB.
Wu LL, Li XY, Deng K, Lin BL, Deng H, Xie DY, Zhang GL, Zhao QY, Mo ZS, Huang YH, Gao ZL.   +10 more
europepmc   +2 more sources

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. [PDF]

Microorganisms, 2021
Serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) is correlated with covalently closed circular DNA. We aimed to investigate the utility of serum HBV pgRNA in chronic hepatitis B patients receiving nucleos(t)ide analogue treatment and those achieving ...
Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT.   +5 more
europepmc   +2 more sources

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination [PDF]

BMC Gastroenterology, 2014
Some reports have documented the coexistence of Hepatitis B surfage Antigen (HBsAg) and anti-HBsAg antibodies (HBsAb) in patients with chronic hepatitis B (CHB), often in the absence of amino acid substitutions in the HBsAg sequences of the Hepatitis B Virus (HBV) genome able to explain an immunological escape variant.HBV genome has a very compact ...
Galati, Giovanni, De Vincentis, Antonio, Vespasiani-Gentilucci, Umberto, Gallo, Paolo, Vincenti, Donatella, Solmone, Maria Carmela, Dell’Unto, Chiara, Picardi, Antonio   +7 more
openaire   +2 more sources